Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-31
2009-12-29
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07638492
ABSTRACT:
The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response.
REFERENCES:
patent: 5698520 (1997-12-01), Honjo et al.
patent: 6803192 (2004-10-01), Chen
patent: 6808710 (2004-10-01), Wood et al.
patent: 2002/0055139 (2002-05-01), Holtzman et al.
patent: 2006/0153841 (2006-07-01), Freeman et al.
patent: 2007/0122378 (2007-05-01), Freeman et al.
patent: 1074617 (2000-07-01), None
patent: WO-95/03408 (1995-02-01), None
patent: WO-01/14556 (2001-03-01), None
patent: WO-01/14557 (2001-03-01), None
patent: WO-01/39722 (2001-06-01), None
patent: WO-02/078731 (2002-10-01), None
Greenwald et al., Annu. Rev. Immunol., 2005, 23: 515-548.
Agata et al., “Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes,” International Immunology 8(5):765-772 (1996).
Bennett et al., “Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses,” The Journal of Immunology 17:711-718 (2003).
Coyle et al., “The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function,” Nature Immunology, 2(3):203-209 (2001).
Dong et al., “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,” Nature Medicine 5(12):1365-1369 (1999).
Ellis et al., “Interactions of CD80 and CD86 with CD28 and CTLA4,” J. Immunol 56:2700-2709 (1996).
Finger et al., “The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors,” Gene 197:177-187 (1997).
Freeman et al., “Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation,” Journal of Experimental Medicine, 192(7):1027-1034 (1998).
Genbank Accession No. AA292201, Hillier et al., (Apr. 21, 1997).
Genbank Accession No. AA399416, Hillier et al., (Apr. 29, 1997).
Genbank Accession No. AF177937, Dong et al., (Jan. 19, 2000).
Genbank Accession No. Q13410, Taylor et al., (Nov. 1, 1997).
Greenfield et al., “CD28/B7 costimulation: a review,” Critical Reviews in Immunology 18:389-418 (1998).
Greenwald et al., “Negative co-receptors on lymphocytes,” Cur. Opin. Immunol 14:391-396 (2002).
Henry et al., “Structure and evolution of the extended B7 family,” Immunology Today 20(6):285-288 (1999).
Honjo, Tasuku, “Seppuku and Autoimmunity,” Science 258:591-592 (1992).
Huang, Z., “Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis,” Pharmacology & Therapeutics 86(3):201-215 (2000).
Ishida et al., “Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death,” The EMBO Journal 11(11):3887-3895 (1992).
Ledbetter et al., “Agonistic activity of a CD40-specific single-chain Fv contructed from the variable regions of mAb G28-5,” Crit. Rev. Immunol. 17:427-435 (1997).
Liang et al., “The right place at the right time: novel B7 family members regulate effector T cell responses,” Cur. Opin. Immunol. 14:384-390 (2002).
Metzler et al., “Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28,” Nature Structural Biol 4:527-531 (1997).
Nishimura et al., “Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice,” Science 291(5502):319-22 (2001).
Nishimura et al., “Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4 CD8) thymocytes,” International Immunology 8(5):773-780 (1996).
Nishimura et al., “Developmental of Lupus-like Autoimmune Diseases by Disruption of the PD-1 gene Encoding an ITM Motif-Carrying Immunoreceptor,” Immunity 11:141-151 (1999).
Nishimura et al., “Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses,” International Immunology 10(10):1563-1572 (1998).
Nishimura et al., “PD-1 Regulates Self-Tolerance to Prevent Tissue Destruction,” Journal of Investigative Dermatology 110(4):477, Abstract No. 25.
Nishimura et al., “PD-1 Regulates Self-Tolerance to Prevent Tissue Destruction,” Journal of Dermatological Science 16(1):S5, Abstract No. 0025.
Nishimura et al., “Facilitation of β Selection and Modification of Positive Selection in the Tymus of PD-1-deficient Mice,” Journal of Experimental Medicine 191(5):891-897 (2000).
Shinohara et al., “Structure and Chromosomal Localization of the Human PD-1 Gene (PDCD1),” Genomics 23:704-706 (1994).
Thilenius et al., “Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants,” Eur. J. Immunol. 27:1108-1114 (1997).
Thompson et al., “The emerging role of CTLA-4 as an immune attenuator,” Immunity 7(4):445-450 (1997).
Vibhakar et al., “Activation-Induced Expression of Human Programmed Death-I Gene in T-Lymphocytes,” Experimental Cell Research 232:25-28 (1997).
Vivier et al., “Immunoreceptor tyosin-based inhibition motifs,” Immunology Today 18:286-291 (1997).
Woronicz et al., “Death Genes in T Cells,” Current Topics Microbiol. Immunol. 200:137-146 (1995).
Anderson, “Nucleic Acid Hybridizataion,” Bio Scientific Publishers (Springer): 1999, p. 82.
Attwood, Teresa K., “The Babel of Bioinformatics,” Science, 290(5491):471-473 (2000).
Bendayan, Moise, Possibilities of False Immunocytochemical Results Generated by The Use of Monoclonal Antibodies: The Example of the Anti-proinsulin Antibody, The Journal of Histochemistry and Cytochemistry, 43(9):881-886 (1995).
Blazar et al., “Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism,” The Journal of Immunology 171:1272-1277 (2003).
Code #'s 27-7975-01, 27-7609-01, 27-7610-01, 27-7856-01, 27-7857-01, or 27-7858-01 in Pharmacia Biotech “BioDirectory” 1997 catalog, p. 44, Pharmacia Biotech Inc., 800 Centennial Ave., Piscataway, New Jersey 08855-1327.
Iwai et al., “Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,” PNAS 99(19):12293-12297 (2002).
Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Press: 1989, p. 9.47-9.57.
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends Biotechnology 18(1):34-9 (2000).
Stedman's Medical Dictionary, 24th Edition, 1982 Williams & Wilkins, Baltimore, MD, p. 42.
Voet et al., In Biochemistry, John Wiley & Sons, 1:126-128 & 230 (1990).
Lederman et al., “A Single Amino Acid Substitution in a Common African Allele of the CD4 Moledule Ablates Binding of the Monoclonal Antibody OKT4,” Molecular Immunology, 28:1171-1181 (1991).
Carninici et al., “High-Efficiency Full-Length cDNA Cloning,” Methods in Enzymology, 303:19-44 (1999).
NCBI Accession No. Q3U472, Carninci et al., Nov. 38, 2006.
Sequence alignment of NCBI Accession No. Q3U472, Carninci et al., Nov. 38, 2006 and SEQ ID No. 2 and SEQ ID No. 4, 1 page.
Freeman Gordon J.
Wood Clive R.
Dana-Farber Cancer Institute Inc.
Foley & Hoag LLP
Genetics Institute LLC
Ouspenski Ilia
LandOfFree
Methods of upmodulating an immune response with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of upmodulating an immune response with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of upmodulating an immune response with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4149401